Intracochlear application of VSF1.01
PreclinicalSmall molecule
Intracochlear application of VSF1.01 is one of 17 small molecule programs targeting Hearing Loss. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Hearing Loss
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Medrol
PfizerApproved
Cipro
BayerApproved
Plaquenil
Jazz PharmaceuticalsApproved
Decadron
AAspen Global Incorporated
Approved
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Rayos
RRoxane Laboratories
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Zonegran
AAzurity Pharmaceuticals
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hearing Loss1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHannover Medical School